Inovio Pharmaceuticals Inc. (INO) News

Inovio Pharmaceuticals Inc. (INO): $2.79

0.16 (+6.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter INO News Items

INO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INO News Highlights

  • INO's 30 day story count now stands at 8.
  • Over the past 26 days, the trend for INO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about INO are AMC, ALKS and BEAT.

Latest INO News From Around the Web

Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.

Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for AMC Entertainment Holdings Inc (NYSE: AMC ), Romeo Power Inc (NYSE: RMO ) and Inovio Pharmaceuticals Inc (NASDAQ: INO ): The latest price target for AMC was by Wedbush on Nov. 4. The analyst firm set a price target … Full story available on Benzinga.com

Benzinga | February 24, 2022

Shareholders in Inovio Pharmaceuticals (NASDAQ:INO) have lost 78%, as stock drops 12% this past week

As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...

Yahoo | February 17, 2022

Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 16, 2022

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

Yahoo | February 15, 2022

Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums

Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.

Yahoo | February 10, 2022

Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth

Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.

Yahoo | February 2, 2022

Could Inovio Pharmaceuticals Become the Next Moderna?

When it comes to biotechs, Moderna (NASDAQ: MRNA) is the standard to beat. On the surface, Inovio is very much in the same position that Moderna was before the pandemic. With a market cap close to $900 million, it doesn't have any recurring revenue or any medicines that are approved for sale, and its coronavirus vaccine program is what originally put it in the limelight in 2020.

Yahoo | February 2, 2022

2 Stocks to Avoid Like the Plague in 2022

The stock market hasn't been in the best shape this year. Growth stocks have been hit particularly hard due to valuation concerns and impending interest rate hikes in the U.S. All these issues are merely temporary, though, and it'd be best for investors to look past them and hold on to shares of great companies. Let's consider two such stocks: Inovio Pharmaceuticals (NASDAQ: INO) and Cronos Group (NASDAQ: CRON).

Yahoo | January 29, 2022

Here's Why Inovio (INO) Looks Ripe for Bottom Fishing

Inovio (INO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | January 25, 2022

Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | January 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5819 seconds.